Aniridia is a devastating ocular disease requiring intensive eye care, social and community support from birth and throughout an individual’s lifetime.

Recent News

© 2019 Aniridia-net.eu – University of Cologne – Webdesign by Effect Group Ltd.

News

COST Association - European Cooperation in Science and Technology through COST Action #18116 @AniridiaNet is glad to host its final Training School that will be held in Tampere (Finland) on 5th - 9th June, 2023. This training school is organized by Prof. Heli Skottman and her team and will focus on 3D bioprinting applications and deep phenotyping of cells. Don't miss out on this exceptional opportunity to learn first-hand, from a expert scientists, including theoretetical & hands-on training sessions. Registrations are OPEN now - deadline by 19th of March, 2023. Please hurry up and get your place! Applicants must email their CV and motivation letter as well as a short description of their current research projects to Dr Rozaliya HRISTOVA (alleta@abv.bg) Please...

Aniridia-Net and Aniridia Europe are happy to announce this new webinar on the regulatory framework of orphan medicional products, presented by Dr. Gloria M. Palomo (Non-Clinical Assessor for the Spanish Medicines Agency), and hosted by Dolores Pérez (Clinical documentation & Advanced Therapy Unit Head, Sermes CRO). Save the date for this meeting with science and aniridia! Friday 20th May 2022 at 13:00 CEST, live streamed in Aniridia Europe’s YouTube Channel There are currently more than 30 million people in the European Union affected by one of the more than 6,000 rare diseases identified to date. There are very few medicines intended for the treatment of rare diseases. To foster development in this area, the European Union's...

Aniridia-Net and Aniridia Europe are happy to announce this new webinar on aniridia, recommended to an audience of professionals working in the field. The speakers, Dr. Juan Álvarez de Toledo (Centro de Oftalmología Barraquer, Barcelona, Spain) and Dr. Paolo Rama (Ospedale San Raffaele, Milan, Italy) have been working since many years with aniridic patients and have a relevant expertise in the field. They belong to Aniridia Europe’s Scientific committee. Introduced by Dr. Giulio Ferrari (Ospedale San Raffaele, Milan, Italy, and a member of the Aniridia-Net Management Committee) they will address the following questions: What is emerging as the most relevant pathologic alteration in aniridia eyes? What can this teach us about inflammation and its management...

Limbal stem cells, are a type of stem cells located in a protected area or “niche” of the border between the cornea and the sclera (the white of the eye). These cells have special characteristics that make them essential for the maintenance of the corneal transparency and therefore for optimal vision. Limbal stem cells (often abbreviated as LSCs) have high proliferative potential as well as the ability to regenerate the corneal epithelium following any damage caused by eyelids, tears or trauma. Also, these cells prevent the white tissue from migrating on to the surface of the cornea. In this webinar presented by Ruby Shalom-Feuerstein and Daniel Aberdam, we will learn a little more about the characteristics, behavior, and specific needs of limbal stem cells, as well as of...

COST Association - European Cooperation in Science and Technology through COST Action #18116 @AniridiaNet is glad to host its first e-Training School on Ocular Surface Disease. Don't miss out on this exceptional opportunity to learn first-hand, from a panel of international scientists and clinical researchers, on the workings of ocular surface imaging, lens and prothesis and ocular surface surgery. Register now to attend to this free all-virtual training program hosted by Vito Romano (from the University of Liverpool). https://esaso.online/join/ Find the training school program HERE. ...